BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26219406)

  • 1. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells.
    Kim SH; Cho YK; Huh JH; Kang JG; Ihm SH; Choi MG; Lee SJ
    Anticancer Res; 2020 Nov; 40(11):6137-6150. PubMed ID: 33109551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Biomed Pharmacother; 2016 Oct; 83():22-32. PubMed ID: 27470546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Endocrinol Invest; 2018 Jun; 41(6):677-689. PubMed ID: 29147952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
    PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Lee SJ
    Endocrine; 2019 Jul; 65(1):110-120. PubMed ID: 31102069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2015 Apr; 48(3):886-93. PubMed ID: 25096912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Anticancer Res; 2015 Oct; 35(10):5453-60. PubMed ID: 26408708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
    Spartalis E; Athanasiadis DI; Chrysikos D; Spartalis M; Boutzios G; Schizas D; Garmpis N; Damaskos C; Paschou SA; Ioannidis A; Tsourouflis G; Dimitroulis D; Nikiteas NI
    Anticancer Res; 2019 Mar; 39(3):1119-1127. PubMed ID: 30842140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.
    Kim SM; Park KC; Jeon JY; Kim BW; Kim HK; Chang HJ; Choi SH; Park CS; Chang HS
    BMC Cancer; 2015 Dec; 15():1003. PubMed ID: 26698299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
    Zhang QC; Jiang SJ; Zhang S; Ma XB
    Asian Pac J Cancer Prev; 2012; 13(7):3471-6. PubMed ID: 22994780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
    Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
    PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
    Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
    BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
    Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
    Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
    J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic effect of celastrol alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Tumour Biol; 2017 May; 39(5):1010428317698369. PubMed ID: 28459364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Tumour Biol; 2017 Feb; 39(2):1010428317692252. PubMed ID: 28218042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.